Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Workforce Reductions in Pharmaceuticals - Outsourcing, External
Innovation and Collaboration Will Drive the Industry Forward
Published on June 2012

Report Summary

Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward

Summary

GBI Research, the leading business intelligence provider, has released its latest research, 'Workforce Reductions in Pharmaceuticals
- Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward'. Job losses within the pharmaceutical industry
are an on-going reality. In the light of this fact, this new report focuses on managing staff during the redundancy process and
managing site closures. It also investigates future outlook for the industry and highlights where the best job opportunities lie.

The report is built using information from primary and secondary research including interviews with experts in the field.

GBI Research analysis shows that all of the biggest pharma companies have been looking hard at the way in which they invest in new
product development. Although companies are adopting a number of different ways of tackling the problems they face, trends that
emerge include a focus on emerging markets both in terms of increasing sales and R&D capabilities; an increasing trend towards
outsourcing of different activities within drug discovery and development; and increasing reliance on products conceived externally to
fuel company pipelines. In order to support innovation externally, companies are spinning out assets whilst retaining an equity stake
and board membership, setting up incubators on company premises to support emerging new companies, supporting life science
research through the development of innovation funds and venture capital groups to invest in early stage research and developing
closer links with academia. Independent bioscience incubators also have a major role to play in supporting the life science
community.

Scope

- Detailed statistics on job losses over the past decade and analysis of the affect of cuts on different job types in different companies.
- Discussion of strategies for improving workforce morale during the redundancy and site closure processes.
- Analysis of site closures across the globe and review of the sale and repurposing of ex-pharma R&D sites.
- Review of the new strategies being adopted by the pharma industry to fuel their future growth and success.

Reasons to buy

- Identify trends in workforce reduction through statistics and in depth discussion of underlying factors leading to the job cuts.
- Develop strategies for managing site closures or redundancies that will help to maintain workforce morale.
- Review the outcomes of site closures in different regions of the globe.
- Understand the ways in which the industry is evolving to meet the new challenges it faces, including greater reliance on external
innovation and increased outsourcing.
- Find examples of successful life science incubators that support new companies in their early years and will help fuel the pharma
pipelines of the future.

Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward (From Slideshare) Page 1/5


Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 State of the Pharmaceutical Industry - Job Cuts and Site Closures 8
2.1 Workforce Reduction 8
2.1.1 Workforce Reduction by Job Type 10
2.1.2 Site Closures 11
2.2 Drivers for Workforce Reduction 14
2.2.1 Mergers and Acquisitions 14
2.2.2 Approval Rates and R&D Expenditure 14
2.2.3 Growth of Generic Medicines 20
2.2.4 Personalized Medicine and Diagnostics 23
2.3 Future Outlook 23
2.3.1 R&D Budgets 23
3 Managing Staff During the Redundancy Process 25
3.1 Managing the Transition 25
3.1.1 Communicating with Employees Across the Organization 25
3.1.2 Employee Consultations and Redundancy Conditions 26
3.1.3 Supporting Employees during the Transition 28
3.2 Productivity Following Restructuring 29
3.2.1 Costs Associated with Restructuring Companies 29
3.2.2 Morale 30
3.3 Conclusions 31
4 Managing Site Closures 32
4.1 Site Redesign: Selling and Repurposing Sites 34
4.1.1 Selling to CROs: GlaxoSmithKline's Zagreb and Verona Sites 35
4.1.2 Case Study: Pfizer's Ann Arbor Site 35
4.1.3 Case Study: AstraZeneca's Lund and Charnwood Sites 35
4.1.4 Case Study: Pfizer's Sandwich Site 36
4.2 Conclusion 36
5 Planning for the Future 37
5.1 Emerging Markets 37
5.2 Outsourcing 39
5.2.1 Outsourcing by Big Pharma 39
5.2.2 Small and Specialist CROs 41
5.3 Spin-outs and Licensing 43
5.4 Hubs, Clusters and Life Science Incubators 45
5.4.1 Life Science Incubators 45
5.4.2 Big Pharma Bioscience Incubators 47
5.4.3 Pharma's Growth Close to Hubs and Clusters 48
5.4.4 Working with Academia 48
5.5 Employment Opportunities 49
5.6 Conclusion 49



6 Appendix 51
6.1 Abbreviations 51
6.2 References 51
6.3 Methodology 53
6.3.1 Primary Research 53
6.3.2 Secondary Research 53
6.4 Contacts Us 53
6.5 Disclaimer 54

1.1 List of Tables

Table 1: Workforce Reductions in Pharmaceuticals, Job Losses from Major Pharma Companies by Year (2007-2010) 9
Table 2: Workforce Reductions in Pharmaceuticals, Number of Employees in the Largest Pharma Companies (2005-2010) 9
Table 3: Workforce Reductions in Pharmaceuticals, Employees by Job Function: Novartis (2004 to 2010) 10
Table 4: Workforce Reductions in Pharmaceuticals, Employees by Job Function: GlaxoSmithKline (2004 to 2010) 10
Table 5: Workforce Reductions in Pharmaceuticals, Employees by Job Function: PhRMA Members 2008 and 2009 11
Table 6: Workforce Reduction in Pharmaceuticals, Examples of Pharma R&D Site Closures (2009-2011) 12
Table 7: Workforce Reduction in Pharmaceuticals, Examples of Manufacturing Site Closures (2007-2011) 13
Table 8: Workforce Reduction in Pharmaceuticals, Transition Probability at Each Stage of Clinical Drug Development 16
Table 9: Workforce Reduction in Pharmaceuticals, Loss of US Sales Revenues due to Patent Expiries ($m; 2010-2013) 20
Table 10: Workforce Reduction in Pharmaceuticals, Branded Drugs Patent Expiration Due in 2011 21
Table 13: Workforce Reduction in Pharmaceuticals, Comparison of Key Points of Collective Redundancy Laws in Major EU Countries
26
Table 14: Workforce Reduction in Pharmaceuticals, Outcomes Following Site Closures: Site Sales and Repurposing Activities 34
Table 15: Workforce Reduction in Pharmaceuticals, Big pharma's Core Facilities Located in China, India and Singapore 38
Table 16: Workforce Reduction in Pharmaceuticals, Mergers and Acquisitions of UK Start-up Life Science Companies in 2010 45

1.2 List of Figures

Figure 1: Workforce Reductions in Pharmaceuticals, Job Losses in the US Pharma Industry (2000 to 2010) 8
Figure 2: Workforce Reduction in Pharmaceuticals, FDA Approval Rates and R&D Expenditure, 2004 - 2010 14
Figure 3: Workforce Reduction in Pharmaceuticals, New Molecular Entity Applications to the FDA Centre for Drug Evaluation and
Research, 1996-2010 15
Figure 4: Workforce Reduction in Pharmaceuticals, The Rising Cost of Drug Development 1975-2005 15
Figure 5: Workforce Reduction in Pharmaceuticals, Failure Rates According to Therapeutic Area in Phase II and Phase III/Submission
17
Figure 6: Workforce Reduction in Pharmaceuticals, Reasons for Increasing Failure Rates 18
Figure 7: Workforce Reduction in Pharmaceuticals, Increasing Complexity of Clinical Trials 19
Figure 8: Workforce Reduction in Pharmaceuticals, R&D Budgets of Leading Pharma Companies 2009-2011 (Predicted) 24
Figure 9: Workforce Reduction in Pharmaceuticals, Summary of Locations of R&D Site Closures (2009-2011) 32
Figure 10: Workforce Reduction in Pharmaceuticals, Summary of Locations of Manufacturing Site Closures (2007-2011) 33


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the In
dustry Forward

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward

Recomendados

Recomendados

Mais conteúdo relacionado

Mais de ReportLinker.com

Mais de ReportLinker.com (20)

Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward